Pharmaceutical News

RSS

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

GlaxoSmithKline and Boehringer Ingelheim announced today that the companies have signed a letter of intent for an accelerated development programme for a co-package for Combivir® (lamivudine/zidovudine) and Viramune® (nevirapine) for chronic treatment of HIV infection in the developing world.

12 Jul 2004

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Results from a three year double-blinded trial which compared antiretroviral therapies show that the combination regimens of tenofovir DF and stavudine, are equally effective, though tenofovir DF has more favorable outcomes with respect to cholesterol levels and the nervous system.

11 Jul 2004

Nevirapine effective in reducing the risk of transmission of HIV at birth

A drug called nevirapine has been shown to be effective in reducing the risk of transmission of HIV at birth, but combination therapy of nevirapine and zidovudine does not improve outcomes, according to a study published in the current HIV/AIDS Journal of the American Medical Association.

11 Jul 2004

ATS receives a US $3.8 million order for a manufacturing system for new drug delivery technology

ATS Automation Tooling Systems Inc.has announced it has received a US $3.8 million (CDN $5.0 million) order from one of the world's largest pharmaceutical companies to provide a manufacturing system for a new drug delivery technology.

10 Jul 2004

Health Canada warning on Trazodone interaction with certain medications

Health Canada, in association with Bristol-Myers Squibb Canada, is advising Canadians to consult with their health care professionals if they are currently being treated with the antidepressant trazodone in combination with any of the following medications: ketoconazole (an antifungal agent), ritonavir and indinavir (protease inhibitors used in the treatment of HIV), or carbamazepine (an anti-epileptic therapy).

9 Jul 2004

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

A potent chemotherapy that is highly effective in treating the most common form of childhood leukemia can significantly harm the heart, but findings from a multi-center study

9 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004

Chiron has received a license for its new meningococcal B vaccine for New Zealand

Chiron developed the vaccine, in close collaboration with the New Zealand Ministry of Health and the Norwegian Institute of Public Health, to protect against the specific meningococcal B strain responsible for a 13-year epidemic in the country.

7 Jul 2004

Endo announces agreement With FDA for new trial design of oxymorphone extended-release tablets

Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration

7 Jul 2004

Pfizer focuses on enabling America's 43 million uninsured to obtain medicines at significant savings

Pfizer Inc said today it will launch the pharmaceutical industry's most comprehensive initiative to significantly expand access to prescription medicines across the United States, with a specific focus on enabling America's 43 million uninsured to obtain Pfizer medicines at significant savings.

7 Jul 2004

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models

7 Jul 2004

Report highlights progress on cancer drugs but more can be done

The recent report by NHS Cancer Director Professor Mike Richards on the uptake in the NHS of new cancer drugs makes clear that many more people are getting access to effective cancer drugs evaluated by the National Institute for Clinical Excellence.

4 Jul 2004

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse. We aimed to reduce the 40% relapse rate of 6 months interferon–ribavirin combination therapy by prolonging treatment to 18 months.

4 Jul 2004

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Combination therapy with three generic antiretroviral drugs in a single tablet has been validated for the first time in an open clinical study in a developing country. Follow-up of 60 patients treated in Yaoundé, Cameroon, has demonstrated the excellent efficacy and safety of a generic fixed-dose combination.

2 Jul 2004

Pharmaceutical News

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Nevirapine effective in reducing the risk of transmission of HIV at birth

ATS receives a US $3.8 million order for a manufacturing system for new drug delivery technology

Health Canada warning on Trazodone interaction with certain medications

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

Natural products to be developed as anti-cancer therapeutics

Chiron has received a license for its new meningococcal B vaccine for New Zealand

Endo announces agreement With FDA for new trial design of oxymorphone extended-release tablets

Pfizer focuses on enabling America's 43 million uninsured to obtain medicines at significant savings

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Report highlights progress on cancer drugs but more can be done

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

U.S. drug prices rise by 3.4 percent during the first quarter of 2004, elderly especially hard hit

New drug application for cilansetron, an investigational product for the treatment of irritable bowel syndrome

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

Request for further evidence about the risks and benefits of the painkiller co-proxamol

Alcon updates filing status of RETAANE® new drug application

Oxford Therapeutic Antibody Centre receives Manufacturer’s Authorisation

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News